Level of maternal respiratory syncytial virus (RSV) F antibodies in hospitalized children and correlates of protection
- Resource Type
- Authors
- Mohamed A. Elrayess; Sara Taleb; Gheyath K. Nasrallah; Asmaa Althani; Barney S. Graham; Tracy J. Ruckwardt; Khalid Alansari; Alexandrine Derrien-Colemyn; Hadi M. Yassine
- Source
- International Journal of Infectious Diseases, Vol 109, Iss, Pp 56-62 (2021)
- Subject
- Microbiology (medical)
F-protein
Respiratory Syncytial Virus Infections
Infectious and parasitic diseases
RC109-216
Antibodies, Viral
medicine.disease_cause
Virus
Antibodies
Pregnancy
Respiratory Syncytial Virus Vaccines
medicine
Humans
Respiratory system
Child
Lower respiratory infection
Protection
biology
business.industry
RSV
Neonates
General Medicine
medicine.disease
Antibodies, Neutralizing
In vitro
Titer
Infectious Diseases
Respiratory syncytial virus (RSV)
Bronchiolitis
Respiratory Syncytial Virus, Human
Immunology
biology.protein
Female
Antibody
business
Child, Hospitalized
Viral Fusion Proteins
Vaccine
- Language
- English
- ISSN
- 1201-9712
Background: Respiratory syncytial virus (RSV) is a major cause of lower respiratory infection among children and no vaccine is available. The stabilized form of the fusion (F) protein – pre-F – is a leading vaccine candidate to target different populations, including pregnant women. This study aimed to determine the magnitude and nature of RSV-directed maternal antibodies (matAbs) in hospitalized children with RSV infection. Methods: Sixty-five paired blood samples were collected from RSV-infected children aged